Get the Stockscreener App
59.04
1.67%
0.97
After Hours:
57.78
-1.26
-2.13%
Belite Bio Inc Adr stock is traded at $59.04, with a volume of 48,807.
It is up +1.67% in the last 24 hours and up +0.54% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$58.07
Open:
$57.78
24h Volume:
48,807
Relative Volume:
0.77
Market Cap:
$1.88B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-50.28
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
-0.94%
1M Performance:
+0.54%
6M Performance:
+28.07%
1Y Performance:
+31.49%
1-Day Range:
$56.80
$60.10
1-Week Range:
$56.30
$60.18
52-Week Range:
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
59.04 | 1.88B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks
BLTEBelite Bio, Inc American Depositary Shares Latest Stock News & Market Updates - StockTitan
Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail
Why Oklo Stock Jumped 96% in January - The Globe and Mail
Belite Bio Raises Fresh Capital: $30M Total Potential as Clinical Programs Advance - StockTitan
Belite Bio Announces Registered Direct Offering of $15 Million - GlobeNewswire Inc.
Flow Beverage Corp. Adds José Bautista as Strategic Advisor and Closes Second Tranche of Private Placement of Convertible Debenture Units - The Globe and Mail
Why Dominion Energy Stock Was Falling Today - The Globe and Mail
Leerink Partnrs Increases Earnings Estimates for Belite Bio - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Stake Increased by JPMorgan Chase & Co. - MarketBeat
Where Will Nvidia Stock Be in 3 Years? - The Globe and Mail
Apple Stock Is Off Its Recent Highs, But Is It Poised to Rise Again? - The Globe and Mail
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 60.3% - MarketBeat
Bitcoin: Buy the Dip? - The Globe and Mail
JPMorgan Chase & Co. Grows Stock Holdings in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Is Coffee Moving to Even Higher Highs? - The Globe and Mail
Charter (CHTR) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Are These Renewable Energy Stocks in Trouble, or Are They Ultra-Cheap Buys? - The Globe and Mail
Dollar Gains as Fed Pauses Interest Rate Cuts - The Globe and Mail
Rigetti CEO Responds to Jensen Huang and Mark Zuckerberg on the Future of Quantum Computing - The Globe and Mail
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
2 Artificial Intelligence Stocks You Can Buy and Hold for the Next Decade - The Globe and Mail
4 Soaring Stocks I'd Buy Now With No Hesitation - The Globe and Mail
Analysts Predict 1,250% Upside for This ‘Strong Buy’ Quantum Computing Stock in 2025... But Investors Should Stay Away - The Globe and Mail
XFRA : ICFFRENDE DER HANDELSUNTERBRECHUNG IN DIVERSEN AKTIENTEIL 2 () - Aktiencheck
Belite Bio (NASDAQ:BLTE) Shares Gap Up After Analyst Upgrade - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Benchmark Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - Defense World
Benchmark Boosts Belite Bio (NASDAQ:BLTE) Price Target to $79.00 - MarketBeat
Benchmark sees growth for Belite Bio shares, highlights Tinlarebant's promise in rare diseases - Investing.com
ATS to Participate in the Citi Global Industrial Tech and Mobility Conference - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Trading 5.4% HigherHere's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 60.3% in December - MarketBeat
GAMMA Investing LLC Buys 419 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
If You'd Invested $1,000 in Tesla Stock 10 Years Ago, Here's How Much You'd Have Today - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Down 4.2%Should You Sell? - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Shares Purchased by State Street Corp - Defense World
What is HC Wainwright’s Estimate for MetaVia Q4 Earnings? - Defense World
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Declines By 12.9% - MarketBeat
Stargardt Disease Therapeutics Market Size in the 7MM was ~USD 27 million in 2023, which is expected to increase by 2034, estimated DelveInsight - The Globe and Mail
Stargardt Disease Therapeutics Market Size in the 7MM was ~USD 27 - openPR
Wedbush Just Pushed Tesla Stock to New All-Time Highs. Is It Too Late to Buy? - The Globe and Mail
AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025 - The Globe and Mail
Where Will Costco Stock Be in 3 Years? - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Facebook, UnitedHealth among Friday's market cap stock movers By Investing.com - Investing.com Nigeria
Facebook, UnitedHealth among Friday's market cap stock movers - Investing.com India
Belite Bio (NASDAQ:BLTE) Trading Down 3.4%What's Next? - MarketBeat
Do you want more choice and competition for your Internet service? TELUS is urging Canadians to sign its #YourInternetYourChoice petition - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Down 4.5%Here's What Happened - MarketBeat
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):